The Problem How It Works Regulatory Ecosystem Get in Touch →
SCALE Programme — Health Innovation East

Objective physiological
triage for NHS ADHD
assessment pathways.

NeuroCharge combines HRV and EDA biometric capture to provide clinicians with objective physiological data at the triage stage — deployable at community pharmacy level, complementing NICE NG87.

Live Physiological Capture
MONITORING
HRV
Directional
EDA ~
Electrodermal
Short scan
Duration TBD
Aligned to
SCALE Programme — Health Innovation East
Cambridge Judge Business School Demo Day 2026
NICE NG87 Compatible
ADHD Taskforce Recommendation 10
DCB0129 Aligned
ICO Registered: ZB655593

The NHS ADHD waiting list
is a clinical emergency.

Current triage relies entirely on subjective self-report. No physiological data. No objective signal. Clinicians are making prioritisation decisions without the tools to do so accurately.

2.76M
Estimated waiting for ADHD assessment in England
15yr
Maximum reported wait time in some regions
100%
Current triage tools are subjective — DIVA-5, ASRS, Conners
12×
Regional variation in treatment rates — severe inequity for women and minorities

A pharmacy-based scan.
Objective data. Asynchronous review.

01

Patient Presents at Pharmacy

GP-referred or self-referred patient places palm flat on the NeuroCharge pad. No specialist training required. No appointment needed.

02

Physiological Capture

HRV captured via MAX30102 optical sensor. EDA captured via gold cup electrodes at thenar and hypothenar pads. Short-duration static capture. Non-invasive. Optimal duration to be determined through feasibility study.

03

Asynchronous Clinical Review

Physiological data uploads to a remote clinician dashboard. Reviewed asynchronously. Highest-risk patients prioritised. ~20 minutes of clinician time saved per patient.

Built for the NHS pathway.
From day one.

NC-IUS-001 — Intended Use Statement

v0.1 DRAFT · DCB0129 aligned

NC-HL-001 — Hazard Log

8 hazards documented · DCB0129 aligned

NC-CRMP-001 — Clinical Risk Management Plan

MAUDE review completed 5 April 2026

ICO Registration

ZB655593 · UK GDPR compliant

Clinical Safety Officer

Appointment pending · Required before feasibility study

Targeting MHRA Class IIa classification with UKCA marking.

NeuroCharge is designed from the ground up for the UK regulatory pathway. Every design decision — from sensor selection to data architecture — is made with MHRA Class IIa requirements in mind.

ISO 13485 QMS framework in progress. IEC 60601-1 electrical safety standards — target compliance. HRA ethical approval process to be initiated before any clinical feasibility study.

Early Feasibility Stage — TRL 4

NeuroCharge is the clinical layer
of a complete ecosystem.

Each product addresses a different moment in the neurodivergent experience — from diagnosis to daily functioning.

Clinical Layer

NeuroCharge

Non-invasive HRV + EDA physiological triage device for NHS ADHD assessment pathways. Pharmacy-deployable. MHRA Class IIa target.

Early Feasibility · TRL 4
Intelligence Layer

Neou

Autonomous AI agent — a Prosthetic Prefrontal Cortex. Monitors executive function and acts on behalf of the user when they can't. First paying customer secured.

Live · Founding members open
Intervention Layer

Rezen8

Therapeutic wearable for freeze-state intervention. Bilateral haptic stimulation at the vagus nerve. 40Hz gamma entrainment + 0.1Hz vagal breath-pacing.

Hardware Prototyping
Advocacy Layer

NeuroAdvocate

Self-advocacy toolkit for late-diagnosed neurodivergent adults. Accommodation passports, AI advocacy letters, and workplace rights navigation.

Built · Pre-launch

Ready to explore
early collaboration?

We are engaging clinicians, NHS partners, and strategic advisors. If you're working in ADHD assessment, community pharmacy, or health innovation — we'd like to hear from you.

Contact Amal Omar Explore Neou →